Envestnet Asset Management Inc. Buys 326,260 Shares of Amgen Inc. $AMGN

Envestnet Asset Management Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 19.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,023,566 shares of the medical research company’s stock after purchasing an additional 326,260 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Amgen were worth $732,774,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Baird Financial Group Inc. increased its stake in shares of Amgen by 1.6% during the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after purchasing an additional 5,496 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock valued at $6,664,000 after purchasing an additional 6,356 shares during the last quarter. National Pension Service grew its holdings in Amgen by 4.7% during the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company’s stock worth $405,717,000 after purchasing an additional 55,489 shares during the period. KBC Group NV grew its holdings in Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after purchasing an additional 130,497 shares during the period. Finally, MW Advisory LLC acquired a new position in Amgen during the second quarter worth approximately $1,054,000. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive topline results from the Phase 3 OASIZ 301 trial. Dazodalibep achieved a statistically significant and clinically meaningful improvement in the primary endpoint—change in disease activity from baseline at week 48—in adults with moderate-to-severe systemic Sjögren’s disease. Amgen’s autoimmune drug succeeds in late-stage trial
• Positive Sentiment: The results raised hopes that dazodalibep could become an important new autoimmune-disease product, potentially expanding Amgen’s long-term revenue base. Reports said the treatment showed sustained improvement through week 48. AMGN’s Dazodalibep Meets Goal in Systemic Sjogren’s Disease Study
• Positive Sentiment: Jefferies raised its Amgen price target to $410 from $367 following the data, while Goldman Sachs maintained a Buy rating and $450 target. The favorable views reinforce the perception that Amgen’s pipeline may support further upside. Amgen price target raised by Jefferies
• Neutral Sentiment: Amgen’s shares have recently traded near the $406 level, above the 50-day moving average of $403.52 and well above the 200-day average of $368.01, indicating strong longer-term momentum but also a relatively elevated valuation.
• Negative Sentiment: Bank of America kept an Underperform rating and $317 price target, citing uncertainty around the dazodalibep data. Citi also flagged open questions, while approval filing is expected to depend on results from another trial. Amgen Underperform Maintained
• Negative Sentiment: Erste Group slightly reduced its FY2027 earnings estimate to $24.36 per share from $24.43, underscoring that near-term earnings expectations have not materially improved despite the pipeline news.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research analyst reports. Oppenheimer restated an “outperform” rating on shares of Amgen in a research note on Wednesday. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and dropped their price objective for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. Barclays lifted their target price on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Mizuho upped their price target on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Finally, Royal Bank Of Canada raised their price objective on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $383.46.

Insider Transactions at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Price Performance

Shares of AMGN stock traded down $4.15 during trading on Wednesday, hitting $406.09. The company had a trading volume of 2,814,707 shares, compared to its average volume of 2,757,001. The firm has a market capitalization of $219.54 billion, a P/E ratio of 25.24, a price-to-earnings-growth ratio of 2.84 and a beta of 0.43. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock’s 50-day moving average price is $403.52 and its 200 day moving average price is $368.01.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.